PacBio (PACB) announced a collaboration with iHope to integrate PacBio’s HiFi long-read whole-genome sequencing into iHope’s international network. “We’ve been impressed with the progress iHope has made in getting answers for rare disease patients through the use of genomics and we believe HiFi Long-Read WGS can move the needle even more by finding variants that may have been otherwise missed,” said Christian Henry, President and Chief Executive Officer, PacBio. “HiFi long-read sequencing offers a complete view of the genome, and through this collaboration we aim to help expand iHope’s access to more comprehensive and advanced genomic research technologies that may help support its delivery of precision care. As February is Rare Disease Month, we’re reminded that every patient matters and we’re proud to support iHope’s efforts to help bring clarity and hope.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- PACB Earnings this Week: How Will it Perform?
- Pacific Biosciences Announces Interim Leadership Role Realignment
- Pacific Biosciences Strengthens Balance Sheet via Asset Sale
- PacBio completes sale of short-read sequencing assets
- Pacific Biosciences: Improving Fundamentals, Emerging Growth Catalysts Support Buy Rating and $3 Target
